Think of biotech and the bioeconomy as a broad methodology encompassing all those who use and borrow from biology to produce ...

Spanish biotech Integra Therapeutics has upped its arsenal of gene editing tools by licensing Caszyme’s Cas12I nucleases, the ...

Scientists who want a say in the future of their inventions are once again moving from academia to the C-suite ...

HONG KONG SAR - Media OutReach Newswire – 12 November 2024 - Immuno Cure BioTech (" Immuno Cure "), a clinical-stage ...

Boston has become one of the top places for biotech research, and one of the big players in this space is CRISPR gene-editing ...

Biotech valuations and investing peaked in late 2021, with investors surging into the sector at the height of the Covid-19 ...

Immuno Cure is a clinical stage biotechnology group based in the Hong Kong Science Park, focusing on research and development ...

When tested in mice, the compound—named BBI-2779—shrank gastric tumors and prevented the cancer from developing resistance to ...

Discover the major biotech partnerships, collaborations, and mergers and acquisitions that made headlines in October 2024.

Since it was founded nearly two decades ago, 23andMe has grown into one of the largest biotechnology companies in the world .

The Cas nuclease market is on an upward trajectory, forecasted to grow from $2.75 billion in 2023 to $3.27 billion in 2024, at a CAGR of 18.9%. Key drivers include the rapid advancements in genome ...

GenScript Biotech Corporation ("GenScript"), a global leader in life sciences services and products, has announced the ...